- Home
- RGC vs CRVO Comparison
RGC vs CRVO Comparison
Compare RGC & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$23.00
HOLD
Current Price
$4.21
Company Overview
Basic Information| Metric | RGC | CRVO |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | Hong Kong | United States |
| Employees | 10 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 47.7M |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | RGC | CRVO |
|---|---|---|
| Price | $23.00 | $4.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.50 |
| AVG Volume (30 Days) | ★ 104.8K | 104.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,737,974.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.29 |
| 52 Week Low | $9.39 | $3.58 |
| 52 Week High | $950.00 | $16.50 |
Technical Indicators
Market Signals| Indicator | RGC | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 41.39 |
| Support Level | $20.81 | $3.58 |
| Resistance Level | $26.42 | $5.44 |
| Average True Range (ATR) | 2.17 | 0.52 |
| MACD | -0.31 | 0.10 |
| Stochastic Oscillator | 19.38 | 40.12 |
Price Performance
Historical Comparison RGC
CRVO
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.